Cardio-renal outcomes with long-term alfa enzyme replacement therapy : a 10-year Fabry outcome survey (FOS) analysis
dc.contributor.author | Ramaswami, Uma | pt_BR |
dc.contributor.author | Beck, Michael | pt_BR |
dc.contributor.author | Hughes, Derralynn A. | pt_BR |
dc.contributor.author | Kampmann, Christoph | pt_BR |
dc.contributor.author | Botha, Jaco | pt_BR |
dc.contributor.author | Pintos-Morell, G. | pt_BR |
dc.contributor.author | West, Michael L. | pt_BR |
dc.contributor.author | Niu, Dauming | pt_BR |
dc.contributor.author | Nicholls, Kathy | pt_BR |
dc.contributor.author | Giugliani, Roberto | pt_BR |
dc.date.accessioned | 2019-12-28T04:04:08Z | pt_BR |
dc.date.issued | 2019 | pt_BR |
dc.identifier.issn | 1177-8881 | pt_BR |
dc.identifier.uri | http://hdl.handle.net/10183/204013 | pt_BR |
dc.description.abstract | Purpose: Following the publication of 5-year agalsidase alfa enzyme replacement therapy (ERT) outcomes data from the Fabry Outcome Survey (FOS), 10-year data were analyzed. Patients and methods: FOS (ClinicalTrials.gov identifier: NCT03289065) data (April 2001 to August 2018) were retrospectively analyzed. Estimated glomerular filtration rate (eGFR) and left ventricular mass indexed to height (LVMI) were analyzed after treatment start (baseline) for patients with ≥3 measurements, including baseline and year 10. Results: Median (range) age (years) of the evaluable treated renal cohort at treatment start was 48.8 (17.9–67.3) for females (n=62), 34.4 (18.0–66.8) for males (n=90). With eGFR ≥60 mL/min/1.73 m2 at baseline, mean (95% CI) rate of eGFR change (eGFR/year) over 10 years was relatively stable in females (n=52; −0.55 [−1.12, +0.01]) and slightly declined in males (n=79; −1.99 [−2.45, −1.54]). With impaired kidney function (eGFR <60 mL/min/1.73 m2) at baseline, mean (95% CI) eGFR/year was stable in females (n=10; −0.14 [−1.43, +1.15]) and slightly declined in males (n=11; −2.79 [−4.01, −1.56]) over 10 years. Median (range) age (years) of the evaluable treated cardiac cohort at treatment start was 46.7 (3.7–67.3) for females (n=34), 28.2 (4.0–54.2) for males (n=35). With left ventricular hypertrophy (LVH; LVMI >48 g/m2.7 in females, >50 g/m2.7 in males) at baseline, mean (95% CI) LVMI/year slightly increased over 10 years in females (n=18; +1.51 [+0.91, +2.12]) and males (n=14; +0.87 (+0.19, +1.55). Without LVH at baseline, mean (95% CI) LVMI/year was stable in females (n=16; +0.52 [−0.13, +1.17]) and males (n=21; +0.57 [+0.02, +1.13]) over 10 years. Conclusion: Agalsidase alfa-treated patients with 10-year FOS data and preserved kidney function and/or normal LVMI at baseline remained largely stable; those with decreased kidney function or LVH at baseline experienced modest declines in renal function and/or increases in LVMI. | en |
dc.format.mimetype | application/pdf | pt_BR |
dc.language.iso | eng | pt_BR |
dc.relation.ispartof | Drug design, development and therapy. Auckland. vol. 13 (2019), p. 3705-3715 | pt_BR |
dc.rights | Open Access | en |
dc.subject | Terapia de reposição de enzimas | pt_BR |
dc.subject | Agalsidase alfa | en |
dc.subject | Doença de Fabry | pt_BR |
dc.subject | Enzyme replacement therapy | en |
dc.subject | Fabry disease | en |
dc.subject | Resultado do tratamento | pt_BR |
dc.subject | Cardio-renal outcomes | en |
dc.title | Cardio-renal outcomes with long-term alfa enzyme replacement therapy : a 10-year Fabry outcome survey (FOS) analysis | pt_BR |
dc.type | Artigo de periódico | pt_BR |
dc.identifier.nrb | 001109091 | pt_BR |
dc.type.origin | Estrangeiro | pt_BR |
Este item está licenciado na Creative Commons License
![](/themes/Mirage2Novo//images/lume/cc.png)
-
Artigos de Periódicos (39541)Ciências Biológicas (3081)